Discovery finally wins US FDA's blessing for preemie lung drug
This article was originally published in Scrip
Executive Summary
A cumulative sigh of relief from investors blew shares of Discovery Laboratories as high as 37% in after-hours trading on 6 March on word that the US FDA finally approved the company's humanised surfactant Surfaxin (lucinactant) as a preventive therapy for respiratory distress syndrome (RDS) in premature infants.